Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better link price with value. In this short Discussion Paper, we outline the major issues including the potential benefits of IBP, potential drawbacks, and considerations for implementation. We then ask for your views. To submit your thoughts, please access the survey which accompanies the Discussion Paper. Consultation closing date: Monday, 30 September 2019.
This year, the OHE team published 39 peer reviewed journal articles, gave 58 lectures and conference presentations, posted 22 in-house OHE publications on our website, and hosted 6 lunchtime seminars and our annual lecture.